Thirty-day safety data for the complete study population of the TAXUS IV trial will be presented, as will 12-month clinical follow-up data from the TAXUS I trial. Both presentations will be made on November 18, and the results will be announced in a news release issued by the Company that day.

The Company also announced that results from its FIRE trial, which studied the FilterWire EX(TM) Embolic Protection Device, will be announced later that day at an evening symposium sponsored by Boston Scientific. Preliminary results for the primary safety endpoint -- cumulative incidence of MACE (Major Adverse Cardiac Events) -- will be presented. The results will be announced in a news release issued by the Company on November 19.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies and other factors described in the Company's filings with the Securities and Exchange Commission.